CFB
PCVX icon

Cullen/Frost Bankers’s Vaxcyte PCVX Stock Holding History

Cullen/Frost Bankers’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Sell
466
-9
-2% -$489 ﹤0.01% 1004
2026
Q1 		$27.6K Buy
475
+69
+17% +$3.75K ﹤0.01% 917
2025
Q4 		$18.7K Buy
406
+108
+36% +$4.83K ﹤0.01% 1012
2025
Q3 		$10.7K Sell
298
-82
-22% -$2.72K ﹤0.01% 1062
2025
Q2 		$12.4K Buy
380
+176
+86% +$5.77K ﹤0.01% 1003
2025
Q1 		$7.7K Buy
204
+165
+423% +$13.2K ﹤0.01% 989
2024
Q4 		$3.19K Buy
39
+5
+15% +$496 ﹤0.01% 1079
2024
Q3 		$3.88K Buy
+34
New +$3.06K ﹤0.01% 1037

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cullen/Frost Bankers's PCVX Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Vaxcyte (PCVX) stake by 1.9% in Q2 2026, selling an estimated $489 and leaving 466 shares worth $27.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Cullen/Frost Bankers first reported a position in PCVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $27.6K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Cullen/Frost Bankers held 466 shares of Vaxcyte worth $27.1K as of Q2 2026.
  • Cullen/Frost Bankers sold 9 Vaxcyte shares in Q2 2026, an estimated $489.
  • Vaxcyte made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1004 holding.
  • Cullen/Frost Bankers first reported a position in Vaxcyte in Q3 2024 and has held it in 8 quarters since.
  • Cullen/Frost Bankers's Vaxcyte position peaked at $27.6K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.